Plus Therapeutics, Inc. (PSTV) Q3 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call provides a mixed picture: strong grant funding and private placement bolster financial health, but increased operating losses and competitive pressures weigh negatively. The Q&A reveals synergies in product offerings and promising trial data, yet management's vague responses on grants and compliance raise uncertainties. The financial performance shows improvement in grant revenue but a decline in cash balance. Given these factors, the stock price is likely to remain stable over the next two weeks.
Key Financial Performance
Cash and Investments Balance $4.8 million at September '24, down from $8.6 million at December '23, due to operational expenditures.
DoD Grant Advance Received $0.9 million in October '24 as the first advance from the DoD grant.
CPRIT Grant Revenue $4.4 million year-to-date '24, up from $3.6 million in the same period of '23, due to increased funding for RNL development.
Total Operating Loss $10.8 million year-to-date '24, compared to $9.5 million in the same period of 2023, primarily due to increased spending related to the ReSPECT-LM trial.
Net Loss $9.1 million or $1.46 per share year-to-date '24, compared to a net loss of $9.5 million or $3.54 per share for the same period in the prior year.
Private Placement Financing Closed a private placement financing of up to $19.25 million, with $7.25 million received at closing and up to $12 million remaining available.
Total Cash Position Approximately $27 million when including cash on hand, financing warrants, and committed contractual grant revenue.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
CNSide Cerebrospinal Fluid Assay Platform: The CNSide platform consists of four lab developed tests (LDTs) for diagnosing, treatment selection, and monitoring patients at risk for leptomeningeal metastases (LM) and other CNS malignancies. The commercial launch is planned for January 2025.
Rhenium (186Re) Obisbemeda (RNL): The ReSPECT-LM trial is progressing with a Phase 1 single-administration trial showing favorable safety and efficacy data. A Phase 1 multiple dose administration trial is set to begin enrollment in Q1 2025.
Market Access for CNSide: The company is negotiating with commercial payers to reintroduce the CNSide assay, focusing on regions with high LM patient populations. A limited market release is expected in January 2025.
GMP Manufacturing Expansion: Plus Therapeutics is expanding its GMP manufacturing capabilities through a partnership with SpectronRx, aiming to produce approximately 15,000 doses of RNL per year around the anticipated FDA approval.
Collaboration with Brainlab: A research and collaboration agreement has been established with Brainlab to develop optimized case planning software for convection-enhanced delivery of RNL for brain cancers.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company is navigating complex regulatory requirements, including obtaining CLIA compliance and CMS inspection for the CNSide platform, which could delay commercialization and reimbursement.
Financial Risks: The company reported a decrease in cash and investments from $8.6 million to $4.8 million, indicating potential liquidity challenges. The total operating loss increased to $10.8 million, raising concerns about financial sustainability.
Grant Dependency: The company relies heavily on grants for funding, with significant amounts expected from CPRIT and the Department of Defense. Any changes in grant availability or funding could impact operations.
Supply Chain Challenges: The company is expanding GMP manufacturing capabilities to ensure a reliable supply of RNL, indicating potential risks associated with production scalability and material sourcing.
Competitive Pressures: The market for CNS diagnostics and treatments is competitive, and the company must effectively position its products against established players to capture market share.
Clinical Trial Risks: The success of ongoing clinical trials, such as ReSPECT-LM and ReSPECT-GBM, is critical for future growth. Any adverse events or unfavorable results could hinder progress and investor confidence.
Economic Factors: Economic conditions and changes in healthcare policies could affect funding, reimbursement rates, and overall market dynamics for the company's products.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
ReSPECT-LM Trial: Initiating enrollment in a Phase 1 trial of multiple dose administrations of RNL for treating patients with leptomeningeal metastases (LM) in Q1 2025.
CNSide Assay Platform: Commercial reintroduction of the CNSide test as part of a limited market release in the US in January 2025.
ReSPECT-GBM Trial: Completion of enrollment in the ReSPECT-GBM Phase 2 trial by mid-2025, with data readout in the second half of 2025.
Pediatric Brain Cancer Program: Obtaining IND approval in the first half of 2025 for a Phase 1 trial for children with high-grade glioma and ependymoma.
GMP Manufacturing Expansion: Transitioning to a pilot scale process capable of producing approximately 15,000 doses per year around the time of anticipated FDA approval.
2024 Grant Revenue: Expected to be in the range of $6 million to $7 million.
Cash Position: Approximately $27 million available from cash on hand, financing, and committed contractual grant revenue.
Upcoming Conferences: Substantial presence at the SNO Annual Meeting from November 21 to November 24, 2024, with multiple presentations and updates.
CNSide Assay Reimbursement: Expecting to finalize reimbursement agreements in Q1 2025 after obtaining CLIA compliance.
Overall Financial Outlook: Net loss year-to-date 2024 was $9.1 million, with an operating loss of $10.8 million, reflecting increased spending on clinical trials.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Private Placement Financing: Closed a private placement financing of up to $19.25 million from new healthcare-focused institutional investors and company insiders, with $7.25 million received at closing and up to $12 million remaining available.
CPRIT Grant: Received $3.3 million from CPRIT in Q2 2024, with $7.8 million remaining due on the grant. Expect to receive the next advance of $3.9 million within 90 days.
Department of Defense Grant: Received a $3 million grant to support the upcoming ReSPECT pediatric brain cancer trial, with the first advance of just under $1 million received in October 2024.
Total Cash Position: Total cash on hand, financing warrants fully exercised, and committed contractual grant revenue is approximately $27 million.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How do you view the opportunities for CNSide and RNL in LM as complementary products versus on their own?
A:We continue to see more and more synergies. The acquisition could potentially increase the total addressable market for LM by 2 to 4 times just by improving diagnostic sensitivity. Using circulating tumor cells can be a proxy for survival and disease monitoring, and we see more data supporting this.
Q:What does the landscape look for grants? Has this changed in terms of the opportunities that are available?
A:We think we're in a good spot through the next year as it relates to grants. We have almost $18 million active grant from CPRIT and are hoping for additional capital. We believe there are continued opportunities in Texas.
Q:How do you come up with the 13 millicuries dose to be used in the LM multi-dose study?
A:We found that we were seeing excellent safety and strong response at cohort 4 dose of approximately 44 millicuries, so we decided to fractionate that for the multiple dose approach.
Q:What is the timeline for getting the CLIA compliance and reimbursements for the CNSide assay?
A:We are on track to commercialize the test in Q4 of this year, but we need to get CLIA compliance and the CMS inspection done in Q1. We are negotiating with payers for reimbursement.
Q:Can you elaborate on the therapeutic ratio you are seeing in your trials and safety data profile?
A:The therapeutic ratio for LM is about 50-plus in cohort 4, and greater than 100:1 in cohort 5. We are seeing favorable results compared to other companies.
Q:Can you provide details on your integrated development plan for LM?
A:We will present more at SNO and roll that out over the first part of 2025. There is activity in single dose and potential for advancing to pivotal Phase 2/3 trials.
Q:Review of Unclear Management Responses
A:Management appeared to avoid giving a direct answer regarding the potential impact of changes in the incoming government on grant opportunities, stating it is hard to tell.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Assay Platform
CLIA certificate
CNSide Cerebrospinal
CPRIT grant
Cerebrospinal Fluid
Code
Difficulty
Fluid Assay
LM administration
PLA
Phase administration
RNL LM
RNL millicurie
RNL patient
Sheri
administration dose
agreement place
cohort dose
compliance
delivery
development plan
dos RNL
dose cohort
enrollment ReSPECT
inspection
interval
lab
market access
payer
progression
reimbursement
response survival
symposium
PSTV Transcript
Plus Therapeutics, Inc. (PSTV) Q4 2024 Earnings Call Transcript
Unknown3-27
The earnings call highlighted significant financial risks, including increased operating losses and reduced cash reserves, despite some grant revenue. The Q&A session revealed uncertainties in clinical trials and market strategies, with unclear responses from management. The equity financing and grants provide some financial support, but the lack of clear guidance and potential regulatory hurdles contribute to a negative sentiment. The absence of a new partnership or shareholder return plan further diminishes positive outlook, leading to a likely negative stock price movement.
Plus Therapeutics, Inc. (PSTV) Q3 2024 Earnings Call Transcript
Unknown11-16
The earnings call provides a mixed picture: strong grant funding and private placement bolster financial health, but increased operating losses and competitive pressures weigh negatively. The Q&A reveals synergies in product offerings and promising trial data, yet management's vague responses on grants and compliance raise uncertainties. The financial performance shows improvement in grant revenue but a decline in cash balance. Given these factors, the stock price is likely to remain stable over the next two weeks.
Plus Therapeutics, Inc. (PSTV) Q2 2024 Earnings Call Transcript
Positive8-15
The earnings call reveals strong financial support from grants and financing, alongside significant trial advancements. Despite operating losses, the company showcases strategic growth plans and potential for future revenue, with positive analyst sentiment. The Q&A section highlights optimism for trial enrollments and product commercialization. These factors, coupled with financial backing and expected grant revenue, suggest a positive stock price movement in the short term.
Plus Therapeutics, Inc. (PSTV) Q1 2024 Earnings Call Transcript
Unknown5-16
The earnings call summary presents mixed signals. While there is progress in clinical trials and grant funding, the company's reliance on external funding and potential delays in regulatory approvals and clinical trial enrollment pose risks. The Q&A session highlights management's cautious optimism but also reveals some uncertainties. Despite improved financial metrics, the cash burn rate and dependency on grants raise concerns. Overall, the sentiment is neutral, with no strong catalysts for significant stock price movement in the short term.
PSTV Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
